TrialScope Launches New SaaS Tool, Core Disclosure
JERSEY CITY, NJ, August 3, 2017 – TrialScope, a global clinical trial transparency and compliance solutions company, announced the launch of its newest solution, Core Disclosure. It enables teams to approve disclosure content once and then reuse the disclosure data around the globe.
Core Disclosure addresses the need to streamline the disclosure process and remove wasted time and resources.
The solution works to:
- Reduce risk by including a configurable list of fields and simplified data entry
- Streamline the process, with a single master protocol form that lists key, common data elements across ClinicalTrials.gov and EudraCT
- Easily import and export ClinicalTrials.gov and EudraCT xml
- Alert the user if data entry would cause an error in ClinicalTrials.gov or EudraCT
“Core Disclosure is a market-driven solution that was developed in consultation with our community of disclosure professionals,” said Mark Heinold, TrialScope’s Chief Executive Officer. “As trial disclosure regulations increase, we are thrilled to offer sponsors a solution to streamline the process, allowing them to put the focus back on their trial.”
Core Disclosure, which can be purchased as a standalone solution, was designed to integrate with TrialScope’s other suite of offerings, including ATLAS and PharmaCM.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
FDA Grants Priority Review to Merck’s sBLA for Winrevair After Early Success in ZENITH PAH Trial
July 2nd 2025Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% reduction in major morbidity and mortality events in patients with pulmonary arterial hypertension.
